What it's for (Indications)
- This combination medication, exemplified by formulations containing ergotamine, caffeine, and cyclizine, is primarily indicated for the acute treatment of moderate to severe migraine attacks.
- It may also be used in the acute management of cluster headaches in patients who have not responded adequately to other therapeutic options or for whom other treatments are contraindicated.
- The ergotamine component aims to abort established attacks rather than prevent them, while caffeine enhances its absorption and therapeutic effect, and cyclizine addresses the commonly associated nausea and vomiting.
- It is not intended for the prophylactic treatment of migraines or for the management of tension-type headaches.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of this combination product must be carefully individualized and strictly adhered to, primarily due to the potential for ergotism associated with ergotamine. It is administered orally at the onset of a migraine attack. A typical initial dose involves one to two tablets, followed by additional doses at intervals of at least 30 to 60 minutes if relief is not achieved, up to a maximum recommended dose per attack and per week. The maximum weekly dose is critical to prevent cumulative toxicity and is generally limited to a certain number of tablets to mitigate the risk of ergotism and medication overuse headache. Patients should be advised not to exceed prescribed limits and to avoid daily use, reserving the medication for acute attacks. Discontinuation should be considered if no relief is obtained after the maximum permitted dose. |
Safety & Warnings
Common Side Effects
- Adverse effects associated with this combination are primarily related to the ergotamine component, though caffeine can contribute to CNS stimulation and cyclizine to anticholinergic effects.
- Common side effects include nausea, vomiting (despite cyclizine), abdominal pain, diarrhea, dizziness, lightheadedness, and paresthesia (tingling or numbness) in the extremities.
- More serious, albeit less common, adverse reactions relate to ergotamine's potent vasoconstrictive properties.
- These can include peripheral ischemia manifested by cold, pale, or cyanotic extremities, muscle pain in the limbs, intermittent claudication, and in severe cases, gangrene.
- Cardiovascular effects such as transient tachycardia or bradycardia, local edema, hypertension, angina, and even myocardial infarction or stroke have been reported.
- Central nervous system effects can include anxiety, confusion, and weakness.
- Patients should be instructed to report any unusual or severe symptoms immediately.
Serious Warnings
- Black Box Warning: BLACK BOX WARNING: POTENTIAL FOR SERIOUS AND LIFE-THREATENING ISCHEMIA Co-administration of ergotamine-containing drugs with potent CYP3A4 inhibitors (including protease inhibitors and macrolide antibiotics) is contraindicated. Such co-administration has been associated with severe and prolonged peripheral vasospasm, leading to cerebral ischemia, myocardial ischemia, and/or ischemia of the extremities. In rare cases, these ischemic events have resulted in gangrene requiring amputation or death. Symptoms of ergotism include nausea, vomiting, diarrhea, abdominal pain, and extreme vasoconstrictive effects, potentially resulting in impaired circulation, numbness, tingling, pain, and cyanosis of the extremities. Patients should be thoroughly educated about the signs and symptoms of ergotism and advised to seek immediate medical attention if any occur. Healthcare professionals must meticulously review patient medication lists for potential CYP3A4 inhibitors prior to prescribing this combination drug.
- This medication requires significant caution, particularly due to the ergotamine component.
- Patients with any underlying cardiovascular disease, including hypertension (even if controlled), coronary artery disease, or peripheral vascular disease, are at increased risk of adverse ischemic events and should be closely monitored or, more often, avoid this medication entirely.
- Renal and hepatic impairment can lead to accumulation of ergotamine and enhance toxicity, necessitating dose adjustments or contraindication in severe cases.
- The risk of medication overuse headache (MOH) is substantial with frequent use, potentially exacerbating headache frequency and severity.
- Concomitant use of other vasoconstrictors, such as triptans, other ergot alkaloids, or sympathomimetics, can potentiate ischemic effects and is generally contraindicated.
- Caution is also warranted in the elderly due to increased susceptibility to vasoconstrictive effects and potential for polypharmacy interactions.
- Pregnancy and breastfeeding are significant concerns due to the abortifacient and vasoconstrictive effects on the fetus and infant, respectively.
How it Works (Mechanism of Action)
The therapeutic effect of this combination drug is achieved through the synergistic actions of its three components. Ergotamine, an ergot alkaloid, acts as a partial agonist or antagonist at serotonin (5-HT1B/1D), alpha-adrenergic, and dopamine receptors. Its primary antimigraine action is believed to be mediated through vasoconstriction of dilated intracranial blood vessels and inhibition of neurogenic inflammation via 5-HT1B/1D receptor agonism. Caffeine, a central nervous system stimulant and adenosine receptor antagonist, augments the vasoconstrictive effects of ergotamine and may enhance its gastrointestinal absorption, thereby accelerating its onset of action. Cyclizine, an H1-receptor antagonist with anticholinergic properties, primarily functions as an antiemetic by acting on the chemoreceptor trigger zone (CTZ) and by reducing vestibular stimulation, thus alleviating the nausea and vomiting frequently associated with migraine attacks and potentially with ergotamine itself. These combined mechanisms provide comprehensive acute migraine relief.
Commercial Brands (Alternatives)
No other brands found for this formula.